The US Renal Denervation Market Analysis Executive Summary
Renal denervation uses energy delivered through a catheter to calm nerves near the kidneys and lower hard-to-control high blood pressure.
Key segments of the renal Denervation market include technology (Radiofrequency, Ultrasound and Chemical) and product (Catheters and Generators).
US Renal Denervation Market Dynamics
Market Growth Drivers
Heart disease remains the leading cause of death worldwide. An ageing population, more minimally invasive procedures and strong clinical evidence for newer devices are driving the renal Denervation market.
Opportunity
Less invasive procedures, remote monitoring of implanted devices and rising access to cardiac care in emerging markets give the renal Denervation market room to grow.
Market Restraints
High device prices, the need for trained specialists, reimbursement pressure and product recalls hold back the renal Denervation market.
Competitive Landscape for Renal Denervation Market in US
The renal Denervation market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Key Players
Healthcare Policies and Regulatory Landscape for Renal Denervation Market in US
Renal Denervation in the US: rules, payment and research
The FDA clears or approves medical devices by risk class, through 510(k) clearance, De Novo classification or premarket approval (PMA).[1] Medicare covers people aged 65 and over and some younger people with disabilities, and Medicaid covers many people on low incomes; both are run with the Centers for Medicare & Medicaid Services (CMS).[2] ClinicalTrials.gov lists 13 studies on Renal Denervation that are recruiting, active or about to start in the US.[3] High blood pressure (ages 30–79): 31.6% of adults 30–79 in 2019, the latest WHO figure for the US.[4]
Policy changes and Reimbursement scenario
Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how renal Denervation products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in US.
The renal Denervation market can be segmented based on various criteria, including technology, product and end user. Here's a breakdown of the market segmentation
By Technology
- Radiofrequency
- Ultrasound
- Chemical
By End User
- Hospitals
- Ambulatory Surgical Centers
- Diagnostic Centers
- Home Care Settings
Also active in this area
Other companies that free public records show in this market: trials they lead, US approvals and WHO prequalification. They are not part of our key players research. Each count opens its source.
Source: ClinicalTrials.gov, Active studies (recruiting, about to start or running) each company leads, found with this market's trial search, worldwide. Retrieved 13 Nov 2026.
US 
Canada
China
Japan
Germany
UK
France
Brazil
Italy
India
Ecuador
Saudi Arabia
Spain
Mexico
Australia
Russia
New Zealand
South Africa
UAE
Egypt
Philippines
Hong Kong
Malaysia
Singapore
Thailand
Kenya